Read about the new Rx products featured in April 2017.
SPIRIVA RESPIMAT
Marketed by:
Boehringer Ingelheim
Indication:
The FDA has expanded the indicated for the approved Spiriva Respimat (tiotropium bromide) for the long-term, once-daily maintenance treatment of asthma in individuals 6 years and older.
Dosage form:
Oral inhalation: 1.25 mcg
For more information: spiriva.com
PARSABIV
Marketed by:
Amgen
Indication:
The FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on hemodialysis.
Dosage form:
Injection: 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL
For more information: amgen.com
TRULICITY
Marketed by:
Eli Lilly
Indication:
The FDA approved Eli Lilly’s updated label for its type 2 diabetes drug, Trulicity (dulaglutide), to include use in combination with basal insulin for adults with type 2 diabetes. The FDA included the changes to the approved product labeling to reflect this important information for prescribers.
Dosage form:
Injection: 0.75 and 1.5 mg
For more information: trulicity.com